Abstract: The present invention provides an apparatus and method of generating a set of 8 clock signals nominally spaced at equal 45° intervals by phase interpolation from a set of 4 quadrature reference clocks. The scheme is useful for clock generation for data capture in an oversampled clock/data recovery (CDR) system where the frequency of data sampling is twice that of the frequency of reference clock edges.

Abstract: One embodiment of the present disclosure sets forth an improved way for a node to manage beacon traffic. Specifically, the node determines that a new message is to be transmitted to one or more neighboring nodes. The node assigns a value to the message based on certain message characteristics. The node utilizes this message value to determine whether to unicast the message to each one of the subscribing nodes or to add the message to the node's beacon. If adding the message to the node's beacon results in a beacon length that is above a desired limit, then the node may add a second beacon to carry the new message. One advantage of this approach is that beacon transmission times are kept low in order to reduce the likelihood that the beacon encounters interference from artificial or natural sources, including interference from beacons transmitted by other nodes.

Abstract: In an embodiment of a wireless network, when a node joins the network and receives a routing advertisement, such a node transmits the routing advertisement to all its neighbors. The node then receives transmission from the neighboring nodes indicating interest in joining the advertised network. If more than a threshold number of neighboring nodes are interested in the advertised route, the newly joining node inserts the route advertisement in a beacon transmission. If there is not a threshold level of interest, the node unicasts only to the neighbors who indicated interest in the advertised network. In an embodiment, the node repeats the above steps on a predetermined time basis (e.g., one per day) in order to determine interest in the advertised route that may have newly arisen.

Abstract: A node within a wireless mesh network performs a path analysis on an advertised path to an access point that has a cost value less than the cost value of the current primary path to the access point. Depending on the cost value difference between the respective cost values of the advertised path and the current primary path, the node may perform a different type of path analysis. Based on the result of that path analysis, the node may change paths to the access point and use the advertised path as the primary path. Further, the node maintains a secondary path so that, in the event that the primary path fails, the node can default to using the secondary path.

Abstract: One embodiment of the present invention sets forth a technique for a node within a network to adjust one or more routing parameters based on certain network parameters. A node monitors certain network metrics such as the mean time between routing drops. In response to changes in these network parameters, the node changes certain routing parameters, such as the holddown time. The node may store network metrics and associated routing parameters that result in preferred network operating conditions. The node may pre-load these beneficial settings upon the occurrence of a particular condition such as a system reset of the node. Moreover, a node may share these beneficial settings with neighboring nodes on the same network. One advantage of this approach is that cost savings are achieved when a node within a network may be installed without preconfiguring the node with specific routing parameters.

Abstract: Compounds of formula (I) in free or salt or solvate form, where T1, T2, and T3 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: System and method for mounting one or more photovoltaic modules includes one or more flexible rods, including a first end and a second end opposite the first end, each of the one or more flexible rods further including an inner core and a first jacket surrounding the inner core between the first end and the second end. The first end is configured to be attached to at least one photovoltaic module using one or more first adhesive materials. The second end is configured to be inserted into at least one hole of a modular rail and attached to at least the modular rail using one or more second adhesive materials. The one or more flexible rods are configured to allow at least a lateral movement in a first direction between the photovoltaic module and the modular rail and support at least the photovoltaic module in a second direction.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: Compounds of formula I in free or salt or solvate form, where T1, T2, X, Ra, Rb, R8 and R9 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: A compound of Formula I or a hydrate or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: System and method for interconnecting photovoltaic modules. The system includes a first photovoltaic module and a second photovoltaic module. The first photovoltaic module includes a first bus bar and a first interconnect tab connected to the first bus bar. The second photovoltaic module includes a second bus bar and a second interconnect tab connected to the second bus bar. The system for interconnecting photovoltaic modules additionally includes a module interconnector configured to interconnect the first and the second photovoltaic modules. The module interconnector includes an interconnection component and an interconnection protector. Additionally, the system for interconnecting photovoltaic modules includes a first connection component connecting the interconnection component to the first interconnect tab of the first photovoltaic module and a second connection component connecting the interconnection component to the second interconnect tab of the second photovoltaic module.

Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.